Patents Assigned to Opsona Therapeutics Ltd.
  • Treatment of renal disease
    Patent number: 9234046
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: January 12, 2016
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • Composition and method for treatment of reperfusion injury and tissue damage
    Patent number: 8734788
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: May 27, 2014
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody
    Patent number: 8580255
    Abstract: The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: November 12, 2013
    Assignee: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF RENAL DISEASE
    Publication number: 20120258103
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Applicant: OPSONA Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • COMPOSITION AND METHOD FOR TREATMENT OF REPERFUSION INJURY AND TISSUE DAMAGE
    Publication number: 20120141466
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Application
    Filed: August 4, 2008
    Publication date: June 7, 2012
    Applicant: Opsona Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • COMPOSITION AND METHOD FOR TREATMENT OF REPERFUSION INJURY AND TISSUE DAMAGE
    Publication number: 20110293601
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Application
    Filed: August 4, 2008
    Publication date: December 1, 2011
    Applicant: Opsona Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • COMPOSITIONS AND METHODS FOR MODULATING TLR14 ACTIVITY
    Publication number: 20100297147
    Abstract: Methods and compositions for modulating neural cell function using antagonists of TLR14 are disclosed. In particular, methods for treating, preventing and/or diagnosing TLR14-associated neurodegenerative conditions and/or disorders are disclosed. Screening methods for evaluating TLR14 modulators, e.g., agonists and antagonists, are also disclosed.
    Type: Application
    Filed: October 18, 2007
    Publication date: November 25, 2010
    Applicants: WYETH, OPSONA THERAPEUTICS, LTD.
    Inventors: Katherine Seidl, Ying Gao, Lih-Ling Lin, Aisling Dunne, William John McCormack
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF RENAL DISEASE
    Publication number: 20100278817
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Application
    Filed: July 4, 2008
    Publication date: November 4, 2010
    Applicant: OPSONA Therapeutics Ltd.
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • COMPOSITION AND METHOD FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20100247527
    Abstract: The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.
    Type: Application
    Filed: June 27, 2008
    Publication date: September 30, 2010
    Applicant: Opsona Therapeutics Ltd.
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Koegh, Christopher Locher